ArticleOpen forum infectious diseases2019

No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial.

Jonathan Z Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.